TIM
IBER

Timelo Investment Management’s Ibere Pharmaceuticals IBER Stock Holding History

Timelo Investment Management’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,900
Closed -$146K – 104
2022
Q1 		$146K Hold
14,900
– – 0.11% 92
2021
Q4 		$145K Buy
+14,900
New +$145K 0.08% 105

Other funds holding IBER

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Timelo Investment Management's IBER Position: Q2 2022 in Review

Timelo Investment Management sold out of Ibere Pharmaceuticals (IBER) in Q2 2022, closing a stake of 14,900 shares — an estimated $146K sold.

Timelo Investment Management first reported a position in IBER in Q4 2021 and held it in 2 quarters. The position peaked at $146K in Q1 2022. 46 funds tracked by Wall St. Rank hold IBER as of Q2 2022.

  • Timelo Investment Management reported no remaining Ibere Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Timelo Investment Management sold 14,900 Ibere Pharmaceuticals shares in Q2 2022, an estimated $146K.
  • Timelo Investment Management first reported a position in Ibere Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Timelo Investment Management's Ibere Pharmaceuticals position peaked at $146K in Q1 2022.
  • 46 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q2 2022.

Based on Timelo Investment Management's 13F filing for Q2 2022, filed 1 Aug 2022.